Your session is about to expire
← Back to Search
Pharmacogenomic Testing for Cancer Care
Study Summary
This trial will test whether providing genetic information to cancer care providers helps them to make better decisions about chemotherapy dosing and reduces side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not in a trial that restricts changing doses of certain chemotherapies.I have been treated with fluoropyrimidine or irinotecan before.I understand and can consent to participate in the study.I belong to any gender, race, or ethnic group.My liver function tests are within normal limits.I have been part of a genetic study or had genetic testing for specific genes before.My kidney function is severely reduced.I am being considered for, or have had, a bone marrow, liver, or kidney transplant.I am an adult patient at The University of Chicago Medical Center and will be treated with fluoropyrimidine and/or irinotecan.I have or had leukemia.
- Group 1: Pharmacogenomics Group
- Group 2: Control Group
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper limit of individuals engaged in this clinical experiment?
"Affirmative. The information hosted on clinicaltrials.gov confirms that this medical investigation is actively recruiting participants, having been posted on February 7th 2022 and most recently updated October 20th 2022. Over 860 patients must be recruited from just one site."
Is registration for this research endeavor open at the present moment?
"Affirmative. The clinical trial registry on clinicialtrials.gov confirms that this research, which was originally posted on February 7th 2022, is actively enrolling participants. 860 patients are required for the sole location of this study."
What are the chief goals of this medical experiment?
"This ongoing clinical trial, with a planned duration of 15 months, aims to assess the Grade 3 or Higher Toxicity (Co-Primary Endpoint). Secondary metrics such as Response Rate, Overall Survival, and Progression Free Survival will also be measured based on radiographic evaluation."
Share this study with friends
Copy Link
Messenger